Release date: 2017-03-23
Researchers have found that stem cells from the umbilical cord may be the key to the next generation of autografts, reducing the number of surgeries that newborns need to undergo due to certain congenital heart diseases.
Congenital heart disease (CHD) is the most common birth defect. In the UK alone, 4,000 newborns are diagnosed with CHD every year. Due to advances in treatment and care technology, 8/10 of CHD children can now grow up healthily.
However, the only treatment for these diseases is prosthetic surgery – replacing damaged tissue with a piece of tissue called a graft. Because the child's heart often grows beyond the repaired graft, the child needs to undergo repeated surgery during childhood.
Now, Massimo Caputo and Paolo Madeddu from the Bristol Heart Institute at the University of Bristol have used umbilical cord and placental stem cells to grow a cell transplant that grows like a living tissue, so it can be combined with childhood heart tissue. Growing. This means that this new graft can replace multiple surgeries that require a larger graft because the child's heart needs only one surgery to grow.
These grafts have been tested in animal models that reflect the true condition of the human body, and the researchers examined their ability to grow and regenerate damaged hearts. The researchers also explored which cells are best suited for transplantation, so they can adjust a range of treatments and solutions based on patient needs. With the completion of the first two experiments, the researchers are preparing to open clinical trials for the treatment of newborns.
Massimo Captuo, a professor of congenital heart surgery from the School of Clinical Sciences, said: "We believe that stem cells from the umbilical cord are critical for a new generation of grafts. These grafts grow at the same rate as children, and because they contain the DNA of the recipient itself. Therefore, the risk of transplant rejection is low."
Paolo Madeddu, a professor of cardiovascular medicine from the School of Clinical Sciences, added: "The current treatment regimen is not good for the long-term outcomes of most young patients and can significantly affect their quality of life. By developing these new implants, we hope It can reduce the number of surgeries that a newborn with congenital heart disease must undergo."
Source: Bio Valley (micro signal BIOONNEWS)
Appliers,Clip Applier,Laparoscopic Clip Applicator,Surgical Clip Applier
Qingdao DMD Medical Technology Co., LTD , https://www.conston-tech.com